CSF2 and early-onset autosomal dominant Alzheimer disease: The use of exogenous GM-CSF as a general cognition enhancer despite its pro-inflammatory/immune modulatory activity has gained significant attention, particularly in brain disorders that are associated with chronic inflammation, such as Down syndrome (DS), Alzheimer’s disease (AD), and COVID-19 [52,53].